“In our view, this vaccine fits our plan to develop innovative treatments for this condition. The vaccine has promising preclinical data.”
Researchers at NIDA in
As heroin is too small a molecule to induce antibodies on its own, scientists worked with organic chemists to join the heroin analog to a carrier protein in order to boost its immune-inducing effect.
The preclinical research was funded by NIDA.
WRAIR also leveraged its expertise in novel adjuvants study to boost the immune response of the vaccine.
If additional pre-clinical testing is successful, Opiant intends to work with researchers at the US Military HIV research programme at WRAIR to combine the heroin vaccine with their HIV vaccine candidate.
WRAIR principal investigator
Dr. Crystal said: “With the heroin epidemic reaching astonishing levels, we are driven at Opiant to develop new treatments for this addiction.
“We look forward to completing the preclinical work conducted by WRAIR and advancing into the clinic.
"Whilst our development of NARCAN Nasal Spray to reverse opioid overdose has been a significant effort to address the unfortunate consequences of heroin addiction, we see the vaccine as having potential in addressing the disease itself.”